Related Experiment Video
Updated: Aug 17, 2026
Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
Antisense imaging: where are we now?
1Department of Radiology, University of Massachusetts Medical School, Worcester, MA 01655, USA. donald.hnatowich@umass med.edu
Abstract:
The field of antisense targeting is changing rapidly as additional results from in vitro studies and animal and patient trials become available. While these developments apply primarily to antisense chemotherapy, many have implications for antisense imaging and radiotherapy. It may now be profitable to reconsider antisense imaging in the light of these recent developments. With the benefit of further insight, it may be possible to predict which antisense mechanisms will be preferable for antisense imaging. It is also possible to consider the influences of carriers (vectors) on the targeting of antisense DNA and whether this might improve imaging. Furthermore, estimates showing only low mRNA steady-state copy numbers per cell may be reconsidered in refining predictions of tissue counting rates. Finally, recent results suggest that radiolabeling antisense DNAs may not adversely influence the targeting properties of antisense DNAs.
Insights
Antisense imaging can be reconsidered due to rapid advancements in antisense targeting, including chemotherapy, radiotherapy, and DNA radiolabeling. New insights may refine antisense imaging mechanisms and carrier influences for improved targeting and tissue counting.
Area of Science:
- Biotechnology
- Molecular Biology
- Medical Imaging
Background:
- Antisense targeting is evolving rapidly with new in vitro, animal, and patient trial data.
- Developments in antisense chemotherapy have potential implications for antisense imaging and radiotherapy.
Purpose of the Study:
- To re-evaluate the potential of antisense imaging in light of recent advancements.
- To predict optimal antisense mechanisms for imaging.
- To explore the impact of carriers (vectors) on antisense DNA targeting for imaging.
Main Methods:
- Review of recent in vitro studies, animal, and patient trial data.
- Analysis of antisense targeting mechanisms and their suitability for imaging.
- Consideration of carrier (vector) effects on DNA targeting.
- Re-evaluation of mRNA steady-state copy numbers per cell.
- Assessment of radiolabeling effects on antisense DNA targeting properties.
Main Results:
- Recent developments suggest a renewed profitability in antisense imaging.
- New insights may allow prediction of preferable antisense mechanisms for imaging.
- Carrier (vector) influences on antisense DNA targeting for imaging can be explored.
- Low mRNA copy number estimates may require reconsideration for tissue counting rates.
- Radiolabeling of antisense DNAs appears not to adversely affect their targeting properties.
Conclusions:
- Antisense imaging warrants reconsideration due to rapid progress in the field.
- Further research into antisense mechanisms, carriers, and radiolabeling can optimize antisense imaging.
- Accurate predictions of tissue counting rates may be refined with updated mRNA estimates.
More Related Videos
09:06MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
Published on: October 7, 2025
08:34Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay
Published on: July 15, 2025